Cholesterol lowering in intermediate-risk persons without cardiovascular disease

• Main Authors: Yusuf, Salim, Bosch, Jackie, Dagenais, Gilles, Jun, Zhu, Xavier, Denis, Lisheng, Liu, Md Aris, Mohd Aznan, Mohd Shah, Azarisman Shah, ., et. al
• Format: Article
• Language: English; English
• Published: Massachusetts Medical Society 2016
• Subjects: R Medicine (General); RC Internal medicine; RJ Pediatrics; RZ Other systems of medicine
• Online Access: http://irep.iium.edu.my/50353/7/Cholesterol_Lowering_in_Intermediate-Risk.pdf; http://irep.iium.edu.my/50353/11/DR_AZNAN.pdf; http://irep.iium.edu.my/50353/
• Institution: Universiti Islam Antarabangsa Malaysia

Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years.